Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460530 | 0.81 | MEN1 (0.73) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL10586698 | 0.80 | MEN1 (0.61) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL1460717 | 0.79 | ALDH1A1 (0.80) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL20023283 | 0.79 | ROCK2 (0.82) | ROCK2ROCK1 | |
| SCHEMBL10179696 | 0.78 | TMEM97 (0.52) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL6532132 | 0.78 | CYP1A2 (0.67) | MAPK1ROCK2ROCK1NPC1JAK2 | |
| SCHEMBL6089128 | 0.78 | MEN1 (0.60) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL2569041 | 0.78 | ROCK2 (0.63) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL2845149 | 0.77 | MEN1 (0.65) | MAPK1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL12059977 | 0.76 | CYP19A1 (0.64) | MAPK1MEN1KMT2AROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | MAPK1 396/4885MEN1 2247/4885KMT2A 1089/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | MAPK1 418/4885MEN1 2443/4885KMT2A 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.